Now I have a clear picture. Let me finalize with the calibration analysis.

**Round 1 bracket:** 1.5–3.0

**Round 2 narrowing anchors compared to MOCHA:**

| Anchor | Avg Score | Has Experiments? | MOCHA Comparison |
|--------|-----------|------------------|------------------|
| LST-Bench (`2wwPG1wpsu`) | 2.50 | Yes — 11 models, 14 datasets, finds "Degeneracy" | MOCHA is **clearly worse** — no experiments at all |
| MCIL Benchmark (`gNoqEdT2wO`) | 2.33 | Yes — adapts Flava, runs 5 CL methods | MOCHA is **worse** — MCIL at least produces results |
| Harry Potter (`3ZdGSTxKuy`) | 2.00 | Yes — collects dataset, runs experiments | MOCHA is **comparable but slightly weaker** — no experiments |
| QCA (`Le823SjZEc`) | 3.00 | Yes — method with ablation studies | MOCHA is **clearly worse** |
| scMPT (`nUpM7egYFd`) | 3.40 | Yes — model comparisons, interpretability | MOCHA is **clearly worse** |

MOCHA sits below LST-Bench (2.50) and MCIL (2.33), comparable to Harry Potter (2.00) but without any experimental evidence. **Final score: 2.0.**

Now let me write the final review.

## Summary
MOCHA presents a curated collection of 10 publicly available multi-subject spatially resolved transcriptomics (SRT) cohorts, each combining gene expression matrices, spatial coordinates, H&E images, and pathologist-derived domain annotations. The paper catalogs these datasets (Table 1, Figure 1), reviews standard preprocessing and batch-correction pipelines (Section 3), and briefly surveys three existing multi-sample spatial clustering methods (Section 4). The stated goal is to provide a resource for developing and evaluating multi-sample SRT methods.

## Strengths
- **Clearly stated inclusion criteria with systematic curation approach.** Section 2 describes a reproducible search strategy across 10x Genomics, GEO, and Spatial Research with three concrete selection requirements (cell-by-gene expression count matrix, spatial coordinate matrix, pathologist annotations from H&E). This makes the collection process transparent and verifiable.
- **Broad cohort diversity documented in Table 1 and Figure 1.** The 10 cohorts span breast cancer (4 subtypes), colorectal, kidney, lung, renal, brain (DLPFC), and olfactory bulb tissues across two technologies (10x Visium and ST), with subject counts from 3 to 94. Figure 1 quantifies molecular diversity (# spots, # genes, sparsity) across cohorts, showing meaningful variation that could support generalization testing.
- **Co-registered H&E images paired with molecular and spatial data per sample.** This tri-modal alignment (expression, spatial coordinates, histology) is a genuine asset for methods like BayeSMART that integrate histological information, and this combination is not uniformly available in existing SRT repositories.

## Weaknesses

### Fatal
- **The paper contains no experimental results whatsoever.** There is no Results section, no benchmark evaluation, no demonstration that any method runs on the assembled data, and no analysis of MOCHA's utility. Sections 3 and 4 are purely literature reviews of preprocessing pipelines and existing methods — neither contains a single empirical finding. For a paper whose abstract promises "a curated resource for developing and evaluating multi-sample SRT methods," the complete absence of evaluation means the paper fails to deliver on its own stated contribution. A resource paper that never uses its own data to produce any result has not made a contribution that can be evaluated. This is a structural problem — not something fixable by adding an ablation or two.

### Major
- **The curation value-add is unclear and underspecified.** All 10 cohorts are previously published, publicly available datasets. The paper never clarifies whether the pathologist annotations are original to MOCHA or simply inherited from the original publications. The promised "standardized data organization, efficient storage formats, and protocols for handling batch effects" are described only in general terms — no concrete format specification, data schema, or documentation of the standardization process is provided. If the annotations come from source studies, MOCHA's contribution reduces to gathering and reformatting existing data, and even the reformatting is never concretely specified.
- **The paper lacks the minimum structure expected of a completed contribution.** There is no Results section, no Discussion, no Limitations section, and no Conclusion. The narrative flows directly from the methods survey (Section 4) into References. A reader looking for evidence that MOCHA has been used, tested, or validated finds none.
- **MOB cohort violates the paper's own framing.** With only 1 subject (12 samples from a single mouse), MOB is a technical-replicate dataset, not a multi-subject cohort. This contradicts the paper's motivation of enabling "cohort-level studies that must model biological heterogeneity alongside technical variation" (line 16–17).

### Minor
- **STAGATE is characterized as a multi-sample method when it is not.** STAGATE (Dong & Zhang, 2022) is primarily a single-sample graph-attention autoencoder for spatial domain identification within individual tissue sections. Listing it alongside genuinely multi-sample methods (BayeSMART, BASS) in Table 2 is misleading.
- **No evaluation protocol or metrics are defined.** The paper never specifies what tasks, metrics (e.g., ARI, NMI against pathologist annotations), or evaluation splits should be used with MOCHA. A benchmark resource should define these.
- **Annotation granularity inconsistency is noted but not resolved.** Section 4 mentions grouping annotations into four categories (immune, stroma, tumor, normal) but does not address how differing original annotation resolutions across cohorts are reconciled for cross-cohort evaluation.

### Trivial
- Figure 2 caption contains a typo: "AA standard pipeline" (line 74).

## Nice-to-Haves
- Running the three surveyed methods (BayeSMART, BASS, STAGATE) on MOCHA data using the described preprocessing pipelines and reporting quantitative results would transform this from a proposal into a completed resource paper.
- Clarifying the provenance of annotations (original vs. inherited from source studies) and providing inter-annotator agreement metrics if new annotations were commissioned.
- Adding an evaluation protocol with defined metrics and baselines (e.g., single-sample clustering on expression alone) to contextualize method performance.

## Removed Points
These points are flagged to be removed, treat them with caution:

- **Harsh critic claimed DLPFC used ST platform, not 10x Visium.** This is factually incorrect — Maynard et al. (2021) used the 10x Genomics Visium platform. Removed.
- **Harsh critic questioned whether MOCHA "exists as an accessible resource" as if doubting its existence.** Per hard rules, we do not question the existence of cited resources. The valid concern — that no URL is provided in the main body — is retained as a Major weakness regarding structural completeness rather than an existence challenge.
- **Strength Finder's "Addresses an under-served need"** — removed as generic; the problem importance framing does not constitute a paper-specific strength given the lack of delivered results.
- **Strength Finder's "Practical accessibility through Python/R formatting"** — removed as unsubstantiated; no format specification or access mechanism is provided in the main text to verify this claim.
- **Strength Finder's "Standardized annotation taxonomy across cancer cohorts"** — subsumed into the Minor weakness about annotation granularity since the standardization process is not concretely described.
- **Harsh critic's formatting nitpicks (other than the AA typo)** — removed per hard rules as parser artifacts.

## Novel Insights
None beyond the paper's own contributions. The paper identifies a genuine gap in SRT resources but does not produce insights that advance understanding beyond cataloging what datasets exist.

## Suggestions
- The single highest-priority revision is to add a Results section that runs the methods from Section 4 on the datasets from Section 2 using the pipelines from Section 3, reporting quantitative results against the pathologist annotations. Without this, the paper remains a proposal, not a contribution.
- Provide a concrete access URL and data schema in the main text.
- Add Discussion, Limitations, and Conclusion sections.
- Either remove the MOB cohort or explicitly justify its inclusion as a technical-replicate reference rather than a multi-subject cohort.

## Calibration

| Anchor Paper | Path | Avg Score | Round | Comparison |
|---|---|---|---|---|
| QCA (gene expression prediction) | `Le823SjZEc` | 3.00 | R1 | Has experiments + ablation; MOCHA clearly worse |
| scMPT (LLM + scFM) | `nUpM7egYFd` | 3.40 | R1 | Has model comparisons + interpretability; MOCHA clearly worse |
| BenchMol (MRL benchmark) | `1JgWwOW3EN` | 4.80 | R1 | Comprehensive benchmark with 23 methods; MOCHA far worse |
| Cell Retrieval Benchmark | `iOltCu4TPS` | 5.00 | R1 | 12 methods, multiple settings, notable findings; MOCHA far worse |
| LST-Bench (time-series benchmark) | `2wwPG1wpsu` | 2.50 | R2 | Has experiments (11 models, 14 datasets), finds phenomena; MOCHA worse |
| MCIL Benchmark | `gNoqEdT2wO` | 2.33 | R2 | Adapts model, runs 5 methods, produces results; MOCHA worse |
| Harry Potter (atypical videos) | `3ZdGSTxKuy` | 2.00 | R2 | Collects dataset, runs experiments; MOCHA comparable but slightly weaker |

**Round 1 bracket:** 1.5–3.0. **Round 2 narrowing:** MOCHA sits below LST-Bench (2.50, has experiments + findings) and MCIL (2.33, has experimental results), comparable to the Harry Potter exploratory dataset paper (2.00) but weaker due to the complete absence of any experimental evidence.

MY FINAL SCORE: <score>2.0</score>
MY FINAL DECISION: <decision>Reject</decision>